Európska únia - dánčina - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - airexar spiromax er indiceret til brug kun hos voksne i alderen 18 år og ældre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesygdom (kol)airexar spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+250 mikrogram

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+500 mikrogram

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+250 mikrogram

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+500 mikrogram

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - fluticasonpropionat, salmeterolxinafoat - inhalationsspray, suspension - 25+250 mikrog./dosis

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+250 mikrogram

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - fluticasonpropionat, salmeterol - inhalationspulver, afdelt - 50+500 mikrogram

Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - fluticasonpropionat, salmeterolxinafoat - inhalationsspray, suspension - 25+250 mikrog./dosis

Európska únia - dánčina - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasonpropionat - astma - medicin for obstruktiv sygdomme, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.